非诚勿扰与恶性黑色素瘤

上传人:san****019 文档编号:20624833 上传时间:2021-04-05 格式:PPT 页数:31 大小:2.22MB
收藏 版权申诉 举报 下载
非诚勿扰与恶性黑色素瘤_第1页
第1页 / 共31页
非诚勿扰与恶性黑色素瘤_第2页
第2页 / 共31页
非诚勿扰与恶性黑色素瘤_第3页
第3页 / 共31页
资源描述:

《非诚勿扰与恶性黑色素瘤》由会员分享,可在线阅读,更多相关《非诚勿扰与恶性黑色素瘤(31页珍藏版)》请在装配图网上搜索。

1、“ 非 诚 勿 扰 ” 与 恶 性 黑 色 素 瘤 catalogue What is malignant melanoma? Melanoma triggers and causes Primary sites Clinical characteristics Early clinical performance Late-stage clinical manifestations Pathological type Treatment 2010 melanoma field progress review What is malignant melanoma? Malignant mela

2、noma, also known as melanoma, is the origin of epidermal melanocyte or nevus of malignant tumors. The disease can be seen at any age, more seen in middle- aged and older, women slightly more than men. Melanoma triggers and causes Air pollution To pursue beauty The lack of medicine knowledge Immune d

3、eficiency Abusing the estrogen drugs Malignant transformation of black mole Racial genetic factors Trauma and chronic stimulation factors Air pollution Harmful ultraviolet light and some harmful material in the air make a difference of human skin, causing melanocyte abnormal expression, trigger mela

4、noma. Many people in order to pursue the clean skin to use chemical cosmetics, skin pollution caused by chemical, even someone with chemical mordant purify skin a mole, stimulates the excessive proliferation melanocyte. To pursue beauty Racial genetic factors Malignant melanoma occur in the white ra

5、ce. For the incidence of world each year to less than 1 2/10 million, but Australias Queensland annual incidence of 16/10 million population, it is the worlds leading high incidence of malignant melanoma. Africa and Asian people rarely have the sickness. Primary sites Malignant melanoma 90 % occurs

6、in the skin, the most common in the back, metal- studded ,leg, foot, toe, nail bed, scalp and so on ; a few occurs in vulvae, digestive tract and eyes. Eye lesions and Oral lesions 脉络膜黑色素瘤 口腔黑色素瘤 Generally speaking moles surface is smooth, melanoma of surface is coarser. If the surface is smooth, an

7、d suddenly becomes coarse or , we should pay attention to it. Clinical characteristics Ulceration not only is one of the important melanoma clinical manifestations which is different from mole, but also has the meaning of prognosis than no ulcer. Patients of malignant melanoma generally are the old;

8、 the youth or children melanoma are rare . Early clinical performance Color: a mole increase in size, pigment or darker or lighter, a mole deepen, shiny, appear color changed . Edge: a mole to radiate out in moles expansion, appear around uneven indented change; become irregular or appear satellite

9、form small a mole, or several birthmark fusion, the surface concavo-convex inequality . Surface: rough; Often coarse and accompanied by scale form or flake desquamation. Sometimes have the drainage or ooze blood, higher lesions can face . Lesions surrounding skin :can appear edema or lose skin gloss

10、 or become white, gray. Kakesthesia: a mole without itching or discomfort pain. regional lymph node enlargement, faintly visible blue-black . 早期临床表现 Late-stage clinical manifestations Special type : a small nodular lesion site, the boundary clear, no coated, tan-white or grey- blue, quality of a mat

11、erial is solid. Freckles type :more from the primary lesions malignant freckles ; surface was flat; the edge great irregularity ; the epidermis of tumor block with freckles samples , this type often occur on elderly facial freckles lesions , which is relatively rare. Spread type : its appearance is

12、shallow eczema kind, and its jagged edge is irregular ,with black, grey and pink disorderly color on the surface . Nodular type: tumor nodules are out of the skin surface; the color is dark brown, gray red and rarely colorless. Bump surface is shown more cauliflower shape, polypoid or bacteria shape

13、, often happen ulcers . Pathological type Superficial expandable type: about 70%, it is visible at surface anywhere ; go along the surface to expand, and then expand to the depth , called the vertical development. nodular type: about 15%,vertical development; penetrate to subcutaneous tissue; prone

14、to lymph node metastases; even more deadly. Ephelides type :about 5%,it primary occur in old people facial skin where black freckles long stand; this type do horizontal growth and enlarge 2cm 3cm or more around. Extremity black mole type: about 10% that happens at palms, foot, nail bed and mucous me

15、mbranes. Treatment Surgical treatment : early circumscribed primary foci should be carried out extensively; the scope should be apart from the primary foci 3 5cm ; the primary foci should be excised to subcutaneous tissue and muscle membrane ; when touch the lymph node enlargement, generally speakin

16、g should make lymph node clean; after the operation ,adjuvant chemotherapy and immune therapy is necessary . Biological immune therapy :biological immune therapy via the various biological agents and biotechnology means to enhance immunity and anti- cancer ability to suppress and kill cancer cells;

17、at present, immune cells such as DC cells, CIK cell have applied to clinical therapy, which gains good effects; biological immune therapy is the most effective, security adjuvant therapies. 人类黑色素瘤抗原 Radiotherapy: In addition to some very early freckles type of malignant melanoma are effective, other

18、 primary foci generally have poor curative effect. So we did not use radiation therapy to cure the primary foci, and metastasis adopt radiotherapy. Endocrine therapy : anti-estrogen drugs make some cases even other drug treatment failure cases get curative effect, and make the illness to alleviate.

19、Chemical treatment : Single drug: )亚硝脲类药物 : have certain effect of melanoma. 氮烯咪胺 (DTIC): DTIC has made the treatment of melanoma forward one step, become the most widely used drugs. Each dose for 350mg/m2, repeat 6 days, 28 days for one period of treatment, efficient rate is 35%. Combination: combi

20、nation can improve the efficient, reduce toxicity reaction. DAV case (DTIc、 ACNu、 VCR): the first choice for melanoma chemotherapy regimens. The preparation method: DTIcloo 200mg, 5ACNUl00mgiv d1VCR 2mg iv d1 21 days, each iv d1 repeated 1 time. DDBT case (DTIC、 DDP、 BCNU、 TAM) Method:DTIC220mg/m2,

21、I.V. d1 3/3w, DDP 25mg/m2, i.v.gtt d1 3w, BCNUl 50mg/m2, I.V. d1/6w, TAM 10mgPO, 2 / d. Efficient rate is 52.5%. CBD case (CCNU、 BLM、 DDP) Method: CCNU 80mg/m2, oral, d1/6w, BLMl 5u/m2, I.V. d3 7/6w, DDP 40mg/m2, I.V. d8/6w. Efficient rate is 48%. 2010 melanoma field progress review melanoma treatme

22、nt finally usher a silver lining Resistance to CTLA - 4 single resistance against genetic mutations and (B - RAF and C - KIT) small molecular targeted drugs ,which prolong the survival of advanced melanoma patients and achieve remarkable breakthrough. It is possible for the treatment of advanced mel

23、anoma patients bring thorough revolution. In advanced melanoma chemotherapy , it is still the gold standard that Dacarbazine(达卡巴嗪 ), but efficient rate is only 8 % 12%. Many biological chemotherapy or more medicine chemotherapy period clinical studies has showed high efficient rate. But period contr

24、olled study of overall survival shows havent exceeded single-agent Dacarbazine(达卡巴嗪 ). American ODay report a randomized controlled clinical research about period, its result has significance. The study proved targeted immune therapy drugs Ipilimumab to prolong period melanoma patients survival. Ipilimumab blockade the combination CTLA4 with B7 which can remove anti- tumor immunosuppression, thus ,it really mobilize specificity anti-tumor immune response. THE END!

展开阅读全文
温馨提示:
1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
2: 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
3.本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 装配图网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
关于我们 - 网站声明 - 网站地图 - 资源地图 - 友情链接 - 网站客服 - 联系我们

copyright@ 2023-2025  zhuangpeitu.com 装配图网版权所有   联系电话:18123376007

备案号:ICP2024067431-1 川公网安备51140202000466号


本站为文档C2C交易模式,即用户上传的文档直接被用户下载,本站只是中间服务平台,本站所有文档下载所得的收益归上传人(含作者)所有。装配图网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。若文档所含内容侵犯了您的版权或隐私,请立即通知装配图网,我们立即给予删除!